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ABSTRACT
This article critically reviews the current availability and selected use
of genetic technologies for horses, before undertaking an ethical
evaluation of current practice and regulatory positions in compara-
tive relation to debates surrounding genetic testing, pre-
implantation genetic testing and gene editing in humans. We
argue that genetic testing for hereditary disorders is not only
justified but should be encouraged on welfare grounds and that
genetic testing for performance traits is ethically permissible based
on a restricted imperative to genetically edit horses and horse
embryos to reduce genetic predisposition to disease and injury.
Given the current state of the science, where the effects of gene
editing on health and welfare are currently undetermined, space is
created for an analytical distinction between equine gene editing
for ‘treatment’ and for ‘enhancement’. Gene editing is only justified
for purposes of correcting/preventing disease and injury. Current
regulation is challenged by apparently conflicting welfare-based
ethical imperatives with respect to welfare-based gene editing.
We propose modifications to the blanket bans on gene editing
with a case-by-case assessment of applications to permit gene
editing, based on best welfare interests underwritten by the aim
of facilitating fair sport that adapt WADAs International Standard
for Therapeutic Use Exemptions, adding an important reporting
element. We reject the use of gene editing to obtain currently
prohibited competitive advantages. In order to safeguard the wel-
fare of human and equine athletes, we argue that regulatory insti-
tutions should urgently collaborate to develop cross-sport
international regulations for the use of gene editing, including
obligatory reporting of data about the health and welfare of geneti-
cally edited horses.
KEYWORDS
Equine sport; ethics; genetic
testing; gene editing; equine
welfare
Introduction
The use of genetic technologies within the equine industries has become increasingly
common since the horse genome was published in 2009 (Wade et al. 2009). Testing for
genes coding for disease in adult horses is common clinical practice (Brosnahan, Brooks,
and Antczak 2010), whilst testing of equine embryos was first reported in 2010 (Harper
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2010) and is now available as a commercial service (Choi, Penedo, and Hinrichs 2015).
Identification of ‘candidate genes’ which might be associated with desirable performance
characteristics (Schroder, Klostermann, and Distl 2011) has been used to develop com-
mercial tests which purport to inform breeding and competition decisions (Hill et al.
2010a). Recently, there has been increasing interest in equine gene editing. This initially
centred around the possibility of using genetic editing therapeutically, to correct injury
and disease (Finno and Bannasch 2014; Finno, Spier, and Valberg 2009; Webbon 2012). In
2017 the first report was published of non-therapeutic gene editing of equine embryos
aimed at enhancing performance in the absence of injury or disease (Vichera et al. 2019).
Opinion on whether available genetic technologies should be adopted is divided
within the equine world. Some sectors, for example, the polo industry, have adopted all
of them with enthusiasm. Others, for example, the World Arabian Horse Organisation
(WAHO) and the Federation Equestre Internationale (FEI) (which regulates all Olympic and
additional international horse competitions) have prohibited gene editing but allow
genetic testing. Yet other organisations, for example, the International Federation of
Thoroughbred Breeding Associations (IFTBA) have been hesitant about embracing even
genetic testing.
This article critically reviews the current availability and selective use of genetic
technologies for horses, as a precursor to an ethical evaluation of the status quo in
comparative relation to current discourse and debates surrounding genetic testing, pre-
implantation genetic testing and genetic editing in humans. We consider these argu-
ments in relation to both the general and athlete human and horse populations. We
explore the extent to which arguments relating to athlete autonomy and welfare, and
sports ethics more generally, apply to horses as they do to humans. We conclude that
testing for inherited diseases is an important tool for improving equine health and welfare
and that testing to identify genes coding for desirable traits (including athletic perfor-
mance) is merely a refinement of existing selective breeding practices. Thus, we argue
that such testing is not ethically problematic in non-human animal populations providing
that welfare protection is a guiding principle, but hold that transparency about genetic
testing at the time of sale is a necessary part of good commercial and governance
practices. More positively, we note that gene editing has the potential to improve equine
welfare by reducing the expression of diseases and injuries that have a genetic basis.
Nevertheless, our support for gene editing is not absolute. We note that the effects of
gene editing on health and welfare, particularly when combined with other techniques
such as cloning, are at present undetermined. This makes gene editing ethically distinct
from genetic testing. Gene editing has the potential to adversely as well as positively
affect the health and welfare not only of individual animals but also—if a permanent
alteration to the genome is made through genetic editing of embryos—of future gen-
erations. It has been recently suggested (Naylor 2019) that gene editing in horses will be
used as a model for gene editing in human athletes, both by regulators and by those who
might seek to use the technology to obtain a (prohibited) competitive advantage. We
argue that in order to safeguard the welfare of human as well as equine athletes, the
equine industries should collaborate with urgency to develop cross-sport international
regulations for the use of gene editing and should include obligatory reporting of data
about the health and welfare of genetically edited horses. An opportunity currently exists
to drive ethical consensus and subsequently to implement such systems before the use of
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gene editing in horses becomes widespread, to provide an evidence base for ongoing
ethical decision-making about the use of these technologies.1
Section 1. How are Genetic Technologies Currently Being Used in Horses?
Genetic Testing to Detect Heritable Disease
Testing of Postnatal Horses
Attempts to identify the genetic basis of equine diseases began in the 1990s and
intensified after the publication of the equine genome sequence in 2009 (Brosnahan,
Brooks, and Antczak 2010; Finno, Spier, and Valberg 2009). As of 2019, 237 equine traits or
disorders with a genetic basis have been catalogued (University of Sydney 2019). Genetic
testing may be used in horses to identify ‘carriers’ and thereby avoid heritable disease
(Brosnahan, Brooks, and Antczak 2010). These are animals that appear normal and do not
suffer from the disease themselves, but carry a recessive abnormal gene which is inherited
via an autosomal genetic mechanism. In order for the disease to occur, an animal must
inherit two copies of the defective gene, one from each parent. If carrier animals are
crossed with other carrier animals there is a 1:4 chance of their offspring inheriting two
abnormal copies of the gene and thus suffering from the disease. If they are ‘crossed’ with
non-carrier animals no offspring will suffer from the disease, although 50% of them will
carry the abnormal gene.2
Genetic testing is also used to identify genetic abnormalities that are inherited via
a dominant autosomal mechanism. In these cases, only one copy of the abnormal gene
need to be inherited for the disease to be expressed. In some cases, the expression of the
disease is not always apparent, either because it occurs at different levels of severity or
because its physical effects become obvious only under certain circumstances. For
example, hyperkalemic periodic paralysis (HYPP) of Quarterhorses is an autosomal domi-
nant disease caused by point mutation in the SCN4A gene (Naylor 1994) giving rise to
signs ranging from mild muscle tremors through temporary paralysis to collapse and
death. Those horses which have inherited two copies of the defective gene often exhibit
more severe disease than those which have inherited one copy. Malignant Hyperthermia
Disorder (MH) of Quarterhorses, Paint horses and Appaloosas is an autosomal dominant
disease caused by mutation in the ryanodine receptor 1 (RYR1) (Aleman, Nieto, and
Magdesian 2009). It can cause a hypermetabolic state, which is triggered particularly by
stress and by the use of halothane anaesthesia. Testing for such autosomal dominant
abnormalities helps to identify those horses that carry the defective gene but show only
mild (if any) symptoms, in order to avoid crossing them with similar animals and giving
rise to more severe disease in offspring.
The adoption of equine genetic testing has been largely voluntary, incentivised by
economic loss associated with foals which express the disease. Thus, the WAHO’s
website, for example, states ‘WAHO very strongly supports the concept of voluntary
testing and disclosure’. Some breed registries now insist upon genetic testing for certain
diseases. Examples include the American Quarterhorse Association (AQHA) whose rules
make it mandatory for all stallions to have a DNA profile on record, and to have been
tested for five genetic diseases3 (AQHA 2019a; Jefferies 2019). Furthermore, the AQHA
have recently amended their regulations so that from 1 January 2020 the registration of
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foals which are homozygous positive (Gb/Gb) for GBED; homozygous positive (MH/MH)
or heterozygous (N/MH) for MH; heterozygous positive (N/H) for HYPP or homozygous
positive (HRD/HRD) for HERDA will not be permitted (AQHA 2019b). Many Warmblood
horse breeders and registries now encourage testing of all breeding stock for
Warmblood Fragile Foal Syndrome (for example, SHB (GB) 2019, Hector 2019), whilst
some studbooks such as The Royal Dutch Sporthorse Association (KWPN) and
Hannoveraner Verband have made such testing mandatory for breeding stallions
(KWPN 2019; Verband 2019). Some of the constituent members of the WAHO (for
example, the German Arabian Horse Organisation) have opted to make genetic testing
for cerebellar atrophy and severe combined immunodeficiency syndrome compulsory in
all breeding animals (WAHO 2019a).
Testing of Embryos
Testing equine embryos for heritable disease involves flushing embryos out of the mare’s
uterus, biopsying embryos in-vitro, and testing the embryonic cells thus obtained for
genetic disease (Choi et al. 2010, 2015, Guignot et al. 2015). Only those embryos that are
not carrying abnormal genes coding for the disease of concern are selected for transfer
back into a mare, to develop to term. Transfer may be immediate, or the embryos may be
vitrified (frozen) whilst the results of genetic analysis are awaited. This commercially
available process is equivalent to pre-implantation genetic diagnosis in humans.
Because the testing takes place in-vitro and thus involves embryo flushing and embryo
transfer, it can only be used in those breeds whose studbooks allow the registration of
foals resulting from embryo transfer. Since the studbooks that register racing
Thoroughbreds internationally do not permit embryo transfer, genetic testing of embryos
of racing Thoroughbreds is not currently permissible.
Genetic Testing for Desirable Traits
In both postnatal horses and equine embryos, genetic testing is also carried out for
reasons other than the detection of disease. The aim is to identify animals or embryos
carrying genes coding for traits which breeders find desirable. This includes identification
of sex in embryos (Herrera et al. 2014, 2015; Hinrichs 2018; Hinrichs and Choi 2012) and of
genes coding for coat colour or white markings in embryos and adults (Guignot et al.
2015; Negro et al. 2017; Rieder 2009). The sex of embryos is of interest to those breeders
who consider that one sex performs better than the other in the competition (for
example, anecdotally, polo players favour mares, whereas event riders often favour
(castrated) males). Identification of coat colour is often undertaken simply for commercial
reasons, but in some breeds there exist colour-linked genetic diseases, so that testing for
colour and for disease is combinable. For example, in the American Paint Horse, a breed
genetic mutation (overo lethal white foal syndrome) occurs, which causes complete white
colour and pink skin and also causes an abnormal lack of ganglion cells in the large and
small intestines. This results in severe intestinal tract abnormalities and early death (Finno,
Spier, and Valberg 2009). Since the disease is an autosomal recessive trait, animals are only
affected if they inherit two copies of the defective gene. Genetic testing thus serves the
dual purpose of identifying coat colour and identifying animals carrying the overo lethal
white foal gene in order to avoid crossing them.
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Particular interest has developed in the possibility of testing adult horses for genes
associated with athletic performance. Such testing can be used to inform decisions about
which animals to breed together, or which races (speed or stamina) to select animals for.
Initial research involved the investigation of variations in myostatin gene expression in
racing Thoroughbreds. Myostatin inhibits skeletal muscle growth, and polymorphisms in
the myostatin gene have been found to account for much of the genetic basis of race
distance aptitude in racehorse (Hill et al. 2010a, 2010b, Hill, Ryan, and MacHugh 2012a,
2012b, McGivney et al. 2012; Tozaki et al. 2012). An alternative approach claims to
correlate mitochondrial DNA genes with aptitude for speed or stamina (Harrison and
Turrion-Gomez 2006). Groups of genes associated with the control of substrate utilisation,
insulin signalling and muscle strength have now also been shown to be of relevance to
performance and to gait in non-Thoroughbred horses (for example, Finno and Bannasch
2014; Kristjansson et al. 2014; Sole et al. 2017).
Gene Editing
The sequencing of the equine genome (Brosnahan, Brooks, and Antczak 2010) has
facilitated research to identify the genetic causes of various diseases (Finno and
Bannasch 2014; Webbon 2012), including those relevant to athletic performance such
as disorders of the musculoskeletal (Diesterbeck and Distl 2007; Distl 2013; Mickelson
and Valberg 2015; Naccache, Metzger, and Distl 2018) respiratory (Gerber, Tessier, and
Marti 2015) and neurological (Aleman et al. 2018) systems. The development of gene-
editing techniques has provided a means ‘of making targeted interventions at the
molecular level of DNA or RNA function, deliberately to alter the structural or functional
characteristics of biological entities’ (Nuffield Council of Bioethics 2016). Foremost
amongst current gene-editing techniques is the ‘CRISP- Cas9ʹ system first reported in
2012 (Jinek et al. 2012), which uses guide strands of RNA to identify particular, pre-
determined DNA sequences of interest within a genome, and then uses an endonu-
clease protein which is attached to the guide RNA strand to cut the DNA at the target
site (Nuffield Council of Bioethics 2016). This provides a method of permanently intro-
ducing or eliminating specific genes from the genome. CRISPR-Cas9 systems can also be
modified to perform functions other than cutting; for example, performing epigenetic
modifications to switch target genes on or off (rather than adding or removing genes).
Such refinements to the CRISPR-Cas9 system allow the possibility of altering gene
expression in individuals without making a heritable change to their genome (Nuffield
Council of Bioethics 2016).
The applicability of CRISP-Cas9 systems to equine medicine is limited by the fact that
many equine diseases have a polygenic basis and are strongly influenced by non-genetic
variables such as environment and nutrition. Nonetheless, the possibility of using genetic
editing to influence the expression of disease in horses—whether throughmodification of
the genome of post-natal animals or of equine embryos—is rapidly increasing.4 The
potential to ‘knock out’ genes which control so-called ‘disabling disorders’ in equine
athletes is of particular interest. Furthermore, evidence of genetic variation for fracture
risk (Blott et al. 2014) and heritability of tendon injuries in horses (Welsh et al. 2014) raises
the possibility that genetic editing might be used to reduce the incidence of injury in
equine athletes.
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Recently, scientists at the Kheiron and Lian laboratories in Argentina collaborated to
use CRISPR-Cas9 gene-editing and whole animal cloning techniques (Anon 2017;
Argentinian Government 2018). CRISPR-Cas9 was used to knock out the myostatin gene
(that negatively regulates muscle mass) in fibroblast cells, and the modified fibroblast cells
were then used to create cloned equine embryos by somatic cell nuclear transfer (cloning)
(Vichera et al. 2019). This use of genetic editing goes beyond correction of disorders and
instead aims to enhance physiological limits beyond 'normal’—a possibility that is facili-
tated by increasing understanding of the genetic control of equine performance (Harrison
and Turrion-Gomez 2006; Hill et al. 2010a, 2010b, Hill, Ryan, and MacHugh 2012a, 2012b,
McGivney et al. 2012).5
The main international regulators of equine competition (excepting inter alia polo) do
not allow genetic editing for purposes either of disease correction or ‘enhancement’. The
FEI (F. E. I. 2019) prohibits horses competing following any non-therapeutic use of gene-
editing techniques, or following ‘any form of genetic modification’ (Article 1004 c,d).
Similarly, the International Federation of Horseracing Authorities’ (IFHA’s) Agreement on
Breeding, Racing and Wagering effectively prohibits genetic editing through Section 12,
‘Definition of a Thoroughbred’ that precludes the registration of any foals ‘produced by . . .
any form of genetic manipulation’ (IFHA 2019). Nevertheless, Section 6A of that agree-
ment states that horseracing authorities have the discretion to ‘allow or disallow’ the
racing of horses or their offspring after the administration of genetic therapy’. No such
permission has yet been granted, meaning that the practical status quo is that genetic
editing is not currently allowed for any reason. This is broadly in line with the position in
human sport, where the World Anti-Doping Agency (WADA) prohibits the use of gene
editing for any purpose (Le Page 2017). The enforcement on such bans is, however,
dependent upon the ability to detect genetic editing of an athlete, and such work is
underway in equine doping (Teruaki et al. 2019; Tozaki et al. 2018).
Section 2. A Comparative Ethical Analysis of the Use of Genetic Technologies
in Horses and Humans
Having briefly reviewed the use of genetic technologies in equine sport, we turn now to
consider a range of ethical issues comparing and contrasting human analogues. For the
purposes of this argument, we assume the justifiability of human sporting use of
animals providing that the positive welfare of sentient animals is maximised, and
welfare harms minimised (Campbell 2013a, 2013b, 2016, 2019). We now turn to argu-
ments concerning genetic testing for health limiting conditions and performance
enhancement and later gene editing, before critically presenting the case for the ethical
salience of the distinction.
Ethical Arguments Surrounding Genetic Testing for Inherited Disease
The sequencing of the human genome has made it possible to predict the risk of disease;
identify carriers of disease; and establish pre-natal and clinical diagnoses and prognoses.
Such testing6 of adult and embryonic humans is fraught with ethical problems, which we
do not have space to discuss here but which are reviewed in (Burgess 2001; Nuffield
Council of Bioethics 1993, 2006). Major ethical considerations include:
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(1) Issues of personal autonomy. For example,
● the possibility to give ‘informed consent’ for genetic testing given the complex-
ities surrounding the reliability of such testing and the implications of its results,
despite genetic counselling;
● issues surrounding the testing of minors who are unable to consent;
● The possible existence of ‘a right to know’ and, conversely a ‘right not to know’
and its application for those who do or do not opt for such tests (including family
members); and
● Issues surrounding confidentiality and disclosure—for example, to insurance
companies.
(2) Issues of impact. For example,
● difficulties in assessing individual health risks associated with test results;
● difficulties in assessing the psychological impacts of testing, particularly if no
treatment is available should the test prove positive;
● impact on those identified as carriers, particularly in terms of life chances
andreproductive choices?;
● potential stigmatisation and/or discrimination?
(3) Concerns about a ‘slippery slope’ to eugenic selection.
(4) ‘Rights’ of embryos. For example,
● If pre-implantation genetic testing reveals defective genes those embryos could
be ‘discarded’.
Some of these concerns, such as psychological consequences, clearly do not apply directly
to the genetic testing of horses. Nor are horses capable of consent, though it can be
assumed that their owners are likely to understand the relevant information and thus act
as proper proxies. Other issues are, however, directly applicable to horses. The power of
genetic data is considered exceptional in human medicine (Bains 2010), and is likely to be
so also in the equine sphere. Issues of confidentiality, disclosure and impact that make
human genetic data so powerful are analogous to issues of transparency in equine
medicine. If an owner chooses to have a horse tested (a) questions arise as to proper
access to the data, and claims by various interested parties to have this disclosed; and (b)
adverse results are likely to have an impact on the commercial value of breeding animals.
The use of genetic data to discriminate against certain human individuals or groups can
affect access to healthcare (Geelen et al. 2012). In equine sport, the provision of health
care—including the preventative measure of not crossing two carrier animals—is likely to
be improved by transparent disclosure of genetic testing information to potential pur-
chasers and to the breeding community more generally. The revelation that a stallion is
a carrier of a disease gene, for example, enables not only prospective purchasers of that
stallion’s breeding services but also existing owners of that stallion’s progeny which may
have inherited the deleterious gene to avoid crosses that may result in the expression of
disease (AQHA 2019a; KWPN 2019; SHB (GB) 2019; WAHO 2019b). Assuming that equine
welfare is paramount, the (potential) economic harm of loss of commercial value as the
result of the disclosure of genetic testing results is outweighed by the potential positive
welfare impact upon future generations of animals. Transparent disclosure of genetic
testing results should, therefore, be encouraged and may be facilitated by breed registries
introducing mandatory systems of genetic testing. Selective breeding, as we discuss
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below, is not a problematic concept in horse breeding and ‘slippery slope’ arguments
about eugenics do not appear to apply here (though an extension to more general loss of
species variety cannot be ruled out). The imperative to protect the welfare of animals
under our care (Campbell 2019; RCVS 2012), appears to support the use of genetic
technologies to select against disease.
One of the main concerns surrounding the use of technique of pre-implantation
genetic testing in humans is that it can facilitate discrimination against and even the
killing of ‘disabled’ embryos (Sparrow 2008). This is problematic if one believes that
embryos havemoral status (Robertson 2003). Nonetheless, its use to select against disease
is allowed and/or regulated for in many jurisdictions (Bayefsky 2017). For example, nearly
400 conditions can be tested for using PGD under the regulation of the Human
Fertilisation and Embryology Authority in the UK (HFEA 2019). For reasons which have
been previously explained (Campbell (2018)) we do not believe that the moral status of
equine embryos is such that it protects them from humane death, and that, combined
with the fact that they are incapable of suffering, makes killing them ethically permissible.
Furthermore, whereas using genetic testing of adults to identify carrier animals in order to
cross them only with non-carrier animals still results in a 50% chance of producing carrier
foals, genetic testing of embryos allows the selection only of those embryos which have
two normal copies of the disease gene of concern. If such genetic testing of embryos was
adopted by an entire breed, it would allow the elimination of the undesirable disease
gene in one generation (Hinrichs and Choi 2012). Selecting against and destroying equine
embryos carrying genes which code for the disease is thus not only permissible but
should be encouraged, for the same welfare-promoting reasons as genetic testing of
adult horses should be adopted.
Ethical Arguments Surrounding Genetic Testing for Performance-limiting Genes
In human sport, testing for genetic predisposition to disease that limits performance is
undertaken on the grounds of harm protection. Examples include testing for genetic
predisposition to Achilles tendon and anterior cruciate ligament injury (Posthumus et al.
2010); to sudden cardiac arrest (Anderson, Exeter, and Bowyer 2012; Tiziano et al. 2016);
and to exertional rhabdomyolosis associated with sickle cell anaemia (Taranto et al. 2018).
Such testing is ethically complicated, since tensions exist between the desire to protect
athletes from injury and the protection of athletes’ autonomy; privacy and their right to
informed consent. Whilst some have argued in favour of mandatory testing programmes7
(Ferrari et al. 2015), others argue that non-voluntary testing is unjustifiably paternalistic
(Anderson, Exeter, and Bowyer 2012; Savulescu 2005). Such arguments are complicated
by the fact that there is no absolute link between genetic predisposition to disease or
injury and the actual risk of harm in an individual (Magavern et al. 2017; McNamee et al.
2009).
It is thus important that test results be interpreted by and discussed with medical
professionals (Taranto et al. 2018) and not simply made available upon demand directly to
consumers (Vlahovich et al. 2017; Webborn et al. 2015). Furthermore, testing under-
determines what action should follow—ranging from exclusion from competing (e.g.
for potentially fatal conditions), or the facilitation of informed risk-taking (Magavern
et al. 2017; Williams, Wackerhage, and Day 2016). Additional issues occur surrounding
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whom data should be shared with, and under what conditions, which press hard on the
principle of confidentiality in relation to employers with a commercial interest in such
data.
Genetic testing for predisposition to disease and injury in equine athletes lags far
behind the use of such techniques in human athletes. Nonetheless, a significant genetic
variation for risk of fracture in Thoroughbred racehorses has been identified (Blott et al.
2014), and the traits which are associated with athletic durability investigated (Sole et al.
2017; Velie, Hamilton, and Wade 2016). The genetic basis of equine exertional rhabdo-
myolosis has also been studied (Norton et al. 2016). This is in some ways analogous to the
work on sickle-cell anaemia-related exertional rhabdomyolosis in humans, and will be of
relevance to the welfare of endurance (Nagy, Murray, and Dyson 2014) as well as of
racehorses.
When applied to the relationship between equine athletes and their physicians (veter-
inarians), the principle of paternalism is less contentious than it is when applied to human
sports medicine. The primary obligation of a veterinarian is to protect the health and
welfare of the animals under their care (RCVS 2012). There appears to be a moral
imperative for veterinarians to protect equine athletes, incapable of autonomy, by testing
for genetic predisposition to injury or disease (Webbon 2012), and by limiting an animal’s
activities in the face of adverse results. Yet just as the contract between a sports physician
and an employer may rest with both them and the individual athlete (Anderson and
Gerrard 2005), the contract exists between a veterinarian and the horse owner, not the
equine athlete. This is complicated even further by the fact that the horse owner may be
represented by an intermediary, for example, the trainer or rider (Campbell 2013a, 2013b).
Ethical Arguments Surrounding Genetic Testing for Desirable Traits
We have argued that genetic testing of adult and embryonic horses for the heritable
disease is ethically desirable. We now wish to consider whether there is any ethical
difference between genetic testing of horses for disease, and for desirable traits.
In human medicine, the idea of allowing testing—particularly of embryos—for desir-
able but non health-linked traits is controversial. Savulescu (2001) argued that parents
should not merely be allowed to choose those characteristics which they wish to be
expressed in their children but that they were obliged to choose the best futures for them.
Critics argued that this had echoes of eugenic experiments, and concerns about discri-
mination and promotion of inequality in society have resulted in a body of work arguing
that such selection should not be permitted (Roberts 2002; Wilkinson 2006, 2008). Genetic
testing of existing children to determine their aptitude for various sports—which one
might argue maximises a child’s life opportunities (Camporesi and McNamee 2016)—has
been criticised not only on the grounds that it is currently an unreliable indicator of
athletic ability (Webborn et al. 2015) but also on the grounds that it may interfere with
a child’s ‘right to an open future’ and prevent them from exploring other meaningful
activities (Camporesi 2013; Camporesi and McNamee 2016). Such autonomy-based con-
cerns are not relevant to decision-making about genetic testing in horses. In animals, the
notion of ‘selective breeding’ for non-health related desirable characteristics (e.g. meat
production, or competitive ability) is centuries old. Using genetic testing is merely an
extension of selective breeding. The harms of testing adult animals (taking a hair or blood
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sample for DNA analysis) are minimal. As we have argued above, consent and autonomy-
based considerations that apply to human patients are irrelevant, and concerns about the
moral status of embryos are inapplicable. Providing that transparency about testing at the
time of sale or breeding is insisted upon, there are therefore no convincing ethical reasons
to prohibit genetic testing for desirable characteristics in horses. Enabling breeders to
select for characteristics that make foals more saleable may in the long term reduce the
number of unwanted foals and their abandonment less likely (Leadon, O’Toole, and
Duggan 2012; Snellow 2008).
In a sporting context, similar potential positive welfare effects exist. For example,
Swedish studies across several equine breeds report positive correlations between spe-
cific, identified genes and performance (Kristjansson et al. 2014; Schaefer et al. 2017; Velie
et al. 2018). The aim of such research is to align genetic make-up with use and to improve
welfare by avoiding horses being trained in disciplines in which they are bound to fail. The
success of such programmes is predicated upon the validity of the assumption that
equine athletic performance is at least reasonably significantly determined by genetics
(Asadollahpour Nanaei, Ayatollahi Mehrgardi, and Esmailizadeh 2019; Schroder,
Klostermann, and Distl 2011). International organisations overseeing breeding and racing
of Thoroughbred racehorses have been hesitant to promote this use of genetic testing
(EFTBA 2016), based on the validity of claims to genetic precursors of superior athletic
performance (EFTBA 2016). Similar arguments are made in relation to humans for athletic
aptitude (Roth (2012), Loland 2015, Webborn et al. 2015, Jacob et al. 2018). In equine
sport, examples are given of a Melbourne Cup (long distance) winner whom it is reputed
would, on the basis of genetic testing, be identified as suitable for sprinting, and of ‘one of
the best (sprinting) stallions in the world . . . [who is] believed to be a . . ..predominantly
stamina (genetic) type’ (EFTBA 2016). Such hyperbole undermines welfare-based ethical
arguments in favour of genetic testing for desirable characteristics since such testing may
provide owners with information which misinforms decision-making about horses’ ath-
letic careers. This may actually have adverse welfare consequences, either through caus-
ing owners to aim horses at competitions for which they are not suited, or by destroying
the market for animals with the ‘wrong’ genetic make-up (EFTBA 2016). This could result
in a surplus of unwanted, low-value animals whose welfare is likely to be compromised
(Snellow 2008). Furthermore, the selection on the basis of performance-related genes
could lead to a situation whereby only a relatively small number of horses with a particular
genetic make-up were being bred from. This has the potential to reduce genetic diversity
within a breed (Binns et al. 2012). Thus, whilst genetic testing for desirable athletic traits
may have the potential to improve equine welfare, this prospect is countered by the
uncertain correlation between genetic factors and performance (EFTBA 2016; Guth and
Roth 2013; Webborn et al. 2015), and also by possible unintended welfare consequences.
Ethical Issues Surrounding Genetic Editing in Horses
A recent conference presentation concerning the gene-editing of human embryos in order
to prevent disease provoked public outcry (Cyranoski 2019) and criticism from the academic
community (Li et al. 2019). Although Savulescu et al. (2015) have argued in favour of
allowing continuing research on gene editing of human embryos, others have advocated
extreme caution (Baltimore et al. 2015; Lanphier et al. 2015). Ethical concerns centre around
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economic inequality; absence of consent; opposition to the use of embryos based on their
moral status; and the fact that the safety of gene editing of embryos is unproven and that
off-target effects (edits in the wrong place) and mosaicism (when some cells carry the edit
but others do not) may occur and be passed on to future generations.
In horses, two potential applications of gene editing are clear at this time: (1) gene
editing an existing post-natal animal or (2) gene editing an equine embryo. In both
scenarios—as discussed above—gene editing could be undertaken in order to ‘correct’
a genetic predisposition to disease or injury, or to ‘enhance’ performance beyond ‘normal’
to give a competitive advantage. Notwithstanding the scientific limitations around
achieving either of these goals discussed above, it is foreseeable that more reliable
gene editing of the equine genome in order both to reduce predisposition to disease or
injury, and to positively affect performance will develop. We, therefore, discuss now the
ethical issues surrounding such developments, in order to facilitate proactive regulatory
discussion. Given that the main international regulators of equestrian sport prohibit gene
editing of horses for any reason, we consider whether this stance is ethically justifiable.
The Principle of Justice Applied to Editing the Equine Genome
In sport, the principle of justice (Beauchamp and Childress 2009) is thought critical to
preserve fair play or a ‘level playing field’ (Bloodworth and McNamee 2017; Murray 2017):
the idea that athletic excellence should be determined primarily by merit (Loland and
Hoppeler 2012). Within the philosophy of sport, this is known as the fair equality of
opportunity principle. Complete equality of opportunity is neither necessary nor feasible
given tolerable differences in, for example, luck, performance conditions, skill, wealth, etc.
Equestrian sport does not provide an exception to this framework, but racing may indeed
reduce some inequalities by its handicapping systems. Despite the recognised impossi-
bility of delivering complete equality of opportunity, the notion of ‘fair competition’
permeates equestrian sport. The FEI website, for example, states that the creation of ‘A
universal and level playing field’ is one of its core values, whilst the website of the British
Horseracing Authority (BHA) claims that part of the BHA’s role is to ‘encourage (. . .) the
honest majority to do the right thing, and prevent. the dishonest minority from gaining an
unfair advantage, thus ensuring a level playing field for all’(BHA 2019). In both human and
equine sport part of the argument around considerations of justice involves also those
who might bet on the result, and the need to protect them by ensuring that competitions
are not deceitfully influenced either by the use of prohibited performance-enhancing
substances or methods, or by event manipulation (i.e. ‘fixing’). The combination of gene-
editing techniques having the potential to improve performance whilst being prohibited
by sports’ regulatory bodies would make data about a horse’s genome economically
valuable, and give those with access to it (through legitimate or illegitimate means) an
unfair advantage in a betting marketplace. Gene editing may elicit criticisms of unfairness
in access to technologies. Neuhaus and Parent (2019) have argued that the use of gene
editing is unfair because such technologies will inevitably be expensive, and not all
breeders or owners will be able to afford them. Whilst it is true that gene editing is likely
to be expensive, such concerns are not decisive since access to top stallions in the
marketplace is already a major factor: only those who can afford the highest stud fees
use the best stallions. Since considerable economic inequalities are already tolerated, the
argument that gene editing is unfair or unjust on economic grounds is diminished.8
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In terms of the ‘fair equality of opportunity’, one could argue that proper competition
between animals who have been edited and those who have not requires an outright ban,
as seems to be the position of the IFHA (IFHA 2019) and the FEI (F. E. I. 2019). We note
whilst the reasoning behind such regulation is based in the ethical principle of justice, the
application of the principle—through enforcement of regulation—is necessarily predi-
cated on the availability of reliable tests for gene editing that is nascent in scientific terms
(Teruaki et al. 2019; Tozaki et al. 2018).
One alternative approach to satisfying the principle of fair equality of opportunity,
often mooted in doping debates, would be to run separate races for genetically edited
animals and non-edited animals. Such a proposal falls foul of the validity and reliability
arguments above. It would require complicated classification systems and result in
reduced numbers in races, possibly making them economically unviable or reducing
their appeal to spectators. Moreover, the argument as to whether a horse ought to be
in one category not the other might be difficult and expensive to validate.
A third approach to satisfying demands of fair equality of opportunity would be to
waive the blanket ban on gene editing in favour of a blanket permission. This is analogous
to familiar pro doping arguments. While promoting fairness it risks other ethically desir-
able protections around athlete welfare and widespread paternalistic concerns around
excessive risk-taking by sports institutions such as WADA, the International Olympic
Committee, and international sport federations that fall under their jurisdiction.
It is evident from a consideration of these possible solutions that the principle of fair
equality of opportunity could be satisfied by either acceptance or prohibition of gene
editing. We turn, therefore, to welfare-based consequential harm: benefit analysis to
deliver decisive ethical solutions.
A harm-benefit analysis of the Ethical Issues Surrounding Editing the Equine Genome
The welfare of the horses being used for competitive sport is a matter of increasing public
concern worldwide (for example, Anon 2013; Doherty et al. 2017; McLean and McGreevy
2010; Mullane 2010; von Borstel et al. 2009). If the uncontentious claim that the dominant
ethical concern here is with equine health and welfare is accepted, then it follows that
a harm: benefit analysis is appropriate. Certainly, equine welfare is the priority of the
equine industries and regulators of equestrian sport, and an outright ban on using safe
gene-editing techniques that could enhance equine welfare would run counter to that
priority. Equally, genetic editing has the potential to improve equine welfare by reducing
hereditary predisposition to disease and injury. There are a number of performance-
affecting equine diseases which are already known to have a hereditary basis—for
example, equine exertional rhabdomyolosis (Norton et al. 2016) and osteochondrosis
dissecans (Naccache, Metzger, and Distl 2018). It is also possible that some injuries
which occur during racing (e.g. fractures) may have a hereditary component, or at least
a genetic predisposition to them (Blott et al. 2014). One might initially conclude that the
use of gene-editing technologies that improve health, reduce injury and thus improve
welfare are ethically justified.
Despite its appeal, such a conclusion is permissive, since it fails to account for the
potential adverse consequences of gene-editing techniques concerning ‘off target’
effects, i.e. unanticipated somatic events (Harrison and Hart 2018), including possible
mutagenesis (Gupta et al. 2019). Such effects might be reduced using the CRISPR-Cas9
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system compared to earlier methods of gene editing (Gupta et al. 2019) yet concerns
remain (Cyranoski 2018). The currently unpredictable nature and extent of ‘off target’
effects present a problem in terms of ethical decision-making around the use of gene
editing in horses. Whilst a blanket ban on gene editing potentially prevents or delays
improvements in equine health and welfare, so too might gene editing result in
negative (or potentially negative) welfare impacts. Suppose ‘corrective’ gene editing is
permitted, and an individual animal is treated for some genetically determined physio-
logical abnormality (a so-called ‘disabling disorder’) that limits athletic performance.
Depending on the method used and its targeting, gene editing can result in an altera-
tion to the musculoskeletal system that may not give rise to heritable genomic changes.
The horse’s own performance levels then might exceed its pre-intervention ability, and
it might consequently become an attractive breeding prospect. Nevertheless, subse-
quent progeny would inherit the ‘disabling disorder’, not the genetic ‘correction’, thus
either perpetuating the persistence of such disorders within a breed or making gene
editing inevitable for generations of horses to come. Both outcomes have negative
welfare impacts. Thus, if our primary concern is to improve equine welfare any relaxa-
tion of the current regulations to allow gene editing ‘corrections’ in post-natal horses
should be accompanied by a ban on breeding from animals who have been ‘treated’ in
such a way.9
Where gene editing occurs at the embryonic stage, changes to the genome would very
likely be heritable. In a harm:benefit analysis, the use of gene-editing techniques in equine
embryos to reduce a genetic disposition to disease or injury, therefore, appears to be
justified for future equine generations. It must be noted, however, that the opposite may
also be true: off-target effects will be more serious when editing embryos than when
editing post-natal horses, because of heritability.
Is There an Ethical Distinction between Gene Editing for ‘Correction’ and for
‘Enhancement’?
One temporary solution would be to allow the use of the technique and then properly
evaluate it. In a harm: benefit analysis, one could argue that off-target risks are worth
taking if we are gene editing in order to treat or prevent disease or predisposition to injury
rather than aiming at performance or economic benefits. This argument has beenmade in
relation to gene editing in humans (Vlahovich et al. 2017; WADA 2008) eliciting arguments
about the boundaries of ‘normality’, and thus what constitutes ‘correction’ and what
‘enhancement’.
Any regulatory distinction between ‘gene therapy’ and ‘gene doping’ is proble-
matic given that correction of any disease state which had negative physiological
consequences is likely to enhance athletic performance. Furthermore, although we
know in broad terms what ‘normal function’ of a species or even a breed is, huge
individual variations retain. It is thus very difficult to distinguish with certainty
between gene editing which simply returns an animal to a ‘normal’ level of perfor-
mance (‘correction/therapy’) and gene editing which enhances performance beyond
‘normal’ (‘doping’). Such conundrums in sports ethics stretch beyond the equine
sphere and beyond gene editing. Consider, for example, a situation in which a child
of short stature was treated with growth hormone in the absence of a growth
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hormone deficiency, in order to enhance their growth to a height which is ‘normal’ for
their population. For many sports, the athletic capability of that person as an adult
would have been improved by having been treated with growth hormone as a child.
Has the treatment thus conferred an unfair advantage? The adult person is ‘normal’ in
population terms, but has arguably been enhanced beyond what would have been
‘normal’ for that individual. This is precisely the question asked of the Argentinian
footballer Lionel Messi, who received such treatment for (an alleged) idiopathic short
stature (Sonksen, Cowan, and Holt 2016). Arguably, all therapies might be considered
‘enhancements’ both of an individual and from that individual’s perspective (Holm
and McNamee 2011).
Within a regulatory framework, one way of dealing with the conceptual problems
around ‘normality’ is to avoid the ‘treatment’ (i.e. correction)/‘enhancement’ distinction.
This, however, may facilitate either a blanket prohibition (the current status quo in
human and most equine sport), or a blanket permission. The ethical importance of
the distinction between ‘treatment’ and ‘enhancement’ (e.g. doping) lies in the notion
that ‘gene doping’ (but not gene therapy) contradicts the aims of protecting the
integrity of sport and of maintaining meaningful competition that does not descend
into a biotechnological arms race. This is not a viewpoint adopted by all authors. Miah
(2004) has argued that genetic editing to enhance performance may be seen as a type
of innovation analogous to the use of new equipment, rather than as a type of doping
analogous to the use of prohibited drugs. On similar lines, Savulescu, referenced by
Skipper (2004) has argued that in fact ‘gene doping’ is entirely consistent with the ‘spirit
of sport’ and with a centuries long tradition of trying to optimise performance by any
means necessary or available. Underlying such arguments is an assumption that athletes
should be allowed to exercise unconstrained autonomy when deciding to subject their
bodies, and coerce athletic competitors, to medical or genetic treatments, and that the
fulfilment of the principle of autonomy outweighs any concerns on the part of others
about harms to the athlete.
Without evaluating the de/merits of these permissive postures (Loland and McNamee
2016), these arguments do not apply with the same force to equine sport, since animals
are incapable of exercising autonomy concerning such interventions. Veterinarians, ani-
mal owners and breeders ought to act in the best interests of equine athletes (Campbell
2013a, 2013b) but it is far from certain what this would look like or whether indeed they
do. It follows that significant weight should be accorded to the likelihood of deleterious
effects of gene editing. In terms of benefits, we reject Neuhaus and Parent’s (2019) claim
that gene editing to enhance performance could also improve equine welfare by reducing
‘wastage rates’ (i.e. retirement or euthanasia rates) due to suboptimal performance. That
argument is unconvincing since the limit of what is ‘inadequate’ would merely continue
to shift upwards as equine athletes became increasingly genetically modified, thus
diminishing any potential positional advantage. In such a scenario, wastage rates due
to suboptimal performance remain unaffected.
We conclude that welfare-based harm:benefit analysis, recognising the currently
unpredictable likelihood of off-target and deleterious effects of existing gene-editing
techniques, supports the ethical salience for the distinction between genetic correction
and genetic enhancement in equine sport in the present case.
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A Modified Therapeutic Use Exemption Policy: Permit ‘Therapy’ While Prohibiting
‘doping’
Notwithstanding the acknowledged conceptual challenges, we have argued for the
recognition of an ethical distinction between ‘corrective’ and performance enhancing
gene editing. Regulators are currently challenged by simultaneous, welfare-based ethical
imperatives to allow gene editing in order to improve equine welfare and to prohibit gene
editing in order to protect equine welfare. Such a conundrum is the product of the
uncertain and incomplete state of the science of gene editing. How then should regula-
tion around gene editing and equine sport be structured in order to best protect equine
welfare in the face of such uncertainty?
One possible solution would be to augment the current blanket ban on gene editing
with a case-by-case assessment of applications to permit gene editing, based on an
analysis of best welfare interests and underwritten by the aim of facilitating fair sport.
This would effectively be a modified form of WADAs International Standard for
Therapeutic Use Exemptions (TUE) (WADA 2019a) apt to regulate gene editing. The
TUE systems are well established for the use of medicinal drugs in human sport, where
the primacy of an athlete’s right to treatment is acknowledged. The TUE process is
controversial (Bloodworth, Cox, and McNamee 2018; Fitch 2012) and prone to abuse
(Cox, Bloodworth, and McNamee 2017), such that some authors suggest its abolition on
the grounds of fairness (Dimeo and Møller 2017, 2018). In enabling treatment under
a TUE, the World Anti-Doping Agency (WADA) aims to allow athletes with a genuine
disease state to return to their ‘normal’ functioning levels (WADA 2019b). Some equine
regulators, for example, the FEI, allow the limited use of certain specified drugs in
equine athletes during competition. Other regulators, for example, those governing
racing, insist that equine athletes should be free of the effects of drugs on competition
days. Nevertheless, something like a TUE process might provide a regulatory mechanism
of distinguishing between ‘correction’ and ‘enhancement’ at an individual level, that
currently seems to be impossible at a species (or even breed) level for the reasons
explained above. In order to be effective, compliance with such a TUE system would
need to be enforced via effective testing methods for undeclared, unauthorised gene
editing. Granted such a system will depend on the trustworthiness of the veterinarian
who approves the TUE certificate, as it relies on the trustworthiness of doctors in human
sport.
The TUE system for gene editing in equine athletes would require rigorous provision
for obligatory short, medium and long-term reporting of the health and welfare status of
animals who have been genetically modified, and for independent collection and analysis
of that data. This would have the indirect benefit of facilitating longitudinal health and
welfare data for horses analogous to studies of the health of children conceived using
assisted reproductive techniques (e.g. Fauser et al. 2014; Hansen et al. 2005), promoted in
the UK by the reporting function contained within the Human Fertilisation and
Embryology Act (1990, as updated in 2008). By adopting this rather cautious,’ individual
TUE plus reporting’ approach, regulators may manage to simultaneously promote and
protect equine welfare. Finally, such a ‘TUE plus reporting’ system would provide an
evidence base for ethical decision-making concerning future gene editing in equine
athletes.
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Conclusion
Many of the ethical issues surrounding the use of genetic technologies in humans and
human athletics, most obviously those concerning consent and autonomy, do not apply
to horses or equine athletes. Nevertheless, in light of the fact that horses as complex,
sentient animals are deserving of moral consideration, genetic testing for disorders is not
only justified but should be encouraged on welfare grounds. Whilst testing for perfor-
mance traits to inform breeding decisions is an extension of historic selective breeding in
non-human animals, caution should be exercised in its use due to the possibility of
indirect adverse welfare consequences of ‘wastage’ or abandonment.
The same ethical imperative which should encourage us to test for the heritable
disease should also cause us to genetically edit horses and horse embryos to reduce
genetic predisposition to disease and injury. This positive ethical intervention ought not
to extend permissively as in some slippery slope position. The effects of gene editing on
health and welfare, particularly when combined with other techniques such as cloning,
are at present undetermined. This makes genetic editing ethically distinct from genetic
testing.
Given the current state of science, there is an ambiguous but valuable distinction
between equine gene editing for ‘treatment’ and for ‘enhancement’. Given possible
unpredictable and poorly understood off-target and deleterious effects, we have argued
that gene editing is only justified for purposes of correcting/preventing disease and
injury. As and when the science develops and is refined to abolish negative effects on
health and welfare, genetic editing of horses for enhancement of performance may
become ethically acceptable, based in a harm: benefit analysis. In the meantime, the
welfare of equine athletes and of human athletes for whom equine athletes and sport
may serve as models should be protected by the development of international regulation
and reporting systems akin to WADAs International Standard for Therapeutic Exemptions
for genetic editing in horses.
Notes
1. We acknowledge that the ethical discussion on genetic technologies is hostage to broader
debates around animal welfare. Specifically, ethical arguments about the acceptability of the
use of genetic technologies in horses are inevitably dependent upon one’s view of the moral
status of horses and hence the justifiability of their use by humans. We do not have space
here to consider alternative philosophical views of the moral status of animals, reviewed by
GRUEN, L (2010) The moral status of animals. The Stanford Encyclopaedia of Philosophy.
Available at http:/plato.stanford.edu/archives/fall2010/entries/moral-animal (Accessed
12.02.2020). Throughout our arguments, we adopt a view of the moral status of animals
that has been previously described (CAMPBELL, M.L.H. (2019) How we think about animals.
Ch 1 in Animals, Ethics and Us. 5 M publishing, Sheffield, 1–9): animals are recognised as
sentient beings with interests in having their own welfare protected but whose moral status
is ultimately inferior to that of humans due to animals’ lack of a sense of future. Humans are
expected to pay virtuous attention to animals’ welfare needs—to minimise harms and to
maximise benefits—but human benefits may sometimes be allowed to trump animal harms.
2. Examples of testing for recessive genes which can cause equine disease include testing for
Hereditary Equine Regional Dermal Asthenia Disorder (HERDA) in Quarterhorses (ZÖLDÁG,
L. (2011). Current and relevant genetic diseases of horses. Literature review. Magyar
Állatorvosok Lapja 133(8): 451–463); Severe Combined Immunodeficiency Disorder (SCID) in
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Arabian horses (ALEMAN, M. FINNO, C.J. WEICH, K. AND PENEDO M. C. T. (2018). Investigation
of Known Genetic Mutations of Arabian Horses in Egyptian Arabian Foals with Juvenile
Idiopathic Epilepsy. J Vet Intern Med 32(1): 465–468); and Fragile Foal Syndrome (WFFS) in
Warmblood breeds (Dias, N. M.,. de Andrade, D. G. A Teixeira-Neto, A.R., Trinque, C.M.,
Oliveira-Filho, J.P., Winand, N.J., Araujo, Jr. J.P and Borges A.S. (2019) Warmblood Fragile
Foal Syndrome causative single nucleotide polymorphism frequency in Warmblood horses in
Brazil. Vet J 248: 101–102).
3. The five diseases are HYPP; MH; Glycogen Branching Enzyme Deficiency Disorder (GBED);
Hereditary Equine Regional Dermal Asthenia Disorder (HERDA) and Polysaccharide Storage
Myopathy Disorder (PSSM).
4. This is evidenced by the use of the techniques in other large animals such as pigs and cattle
West, J. and W. W. Gill (2016). Genome Editing in Large Animals. Journal of Equine Veterinary
Science 41: 1–6.
5. At the time of writing, no report of foals being born from the embryos which were genetically
edited in the Kheiron and Lian Laboratories has been published.
6. In human medicine, a distinction is made between ‘genetic testing’, i.e. of an individual in
whom disease is suspected on clinical grounds and ‘genetic screening’, i.e. genetic testing
which is carried out when there is no prior evidence of disease in an individual.
7. For example, the National Collegiate Athletic Association (NCAA) in the USA has a mandatory
testing programme for sickle cell anaemia trait.
8. In human sport, it has been argued on egalitarian grounds that gene editing levels the
playing field Tamburrini, C. M. (2007). ‘What’s wrong with genetic inequality? The impact of
genetic technology on elite sports and society.’ Sport, Ethics and Philosophy 1(2): 229–238.
9. We accept in making this argument that the same argument could be applied to breeding
from animals who have had ‘corrective surgeries’ for conditions with a plausible hereditary
component, for example, recurrent laryngeal neuropathy Gerber, V., C. Tessier and E. Marti
(2015). ‘Genetics of upper and lower airway diseases in the horse.’ Equine Vet J 47(4):
390–397, Draper, A. C. E. and R. J. Piercy (2018). ‘Pathological classification of equine recurrent
laryngeal neuropathy.’ Journal of veterinary internal medicine 32(4): 1397–1409.
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